- Welcome, Preactivity Survey, and Overview of MM in Veterans
- Using Revised Diagnostic and Staging Criteria for MM
- Individualizing Treatment Strategies for Each Patient
- Incorporating Recently Approved and Promising Combinations Into Existing Regimens
- Managing Disease Complications and Treatment-Associated Adverse Events
- Postactivity Assessment, Question and Answer Session, and Closing Remarks
Date / Time
carol huff, MD
Medical Director, Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Medicine and Oncology
Multiple Myeloma Program
Johns Hopkins University
Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Jesús G. Berdeja, MD
Director of Multiple Myeloma Research
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancer
Adam Cohen, MD
Director, Myeloma Immunotherapy
Assistant Professor, Department of Medicine
Abramson Cancer Center of the University of Pennsylvania
Prashant Kapoor, MD
Assistant Professor of Medicine and Oncology
Department of Hematology
Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor of Medicine
Ajay Nooka, MD, MPH, FACP
Division of Bone Marrow Transplant
Department of Hematology and Oncology
Winship Cancer Institute
The goal of this activity is to provide participants with specialized education that addresses the unique needs of veterans with multiple myeloma to improved patient care.
This activity is intended for physicians, registered nurses, and other healthcare professionals who care for patients with myeloma.
- Apply new diagnosis and staging criteria to determine optimal timing of treatment initiation for patients with myeloma
- Plan individualized treatment for patients with newly diagnosed myeloma based on patient characteristics and tumor biology/genetics using current guidelines and emerging therapeutic options
- Integrate recently approved agents into existing treatment strategies for patients with relapsed/refractory myeloma
- Manage disease-related and treatment-related symptoms in patient with myeloma
Physician Continuing Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
1.0 contact hour may be earned for successful completion of this activity.
California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13664, for 1.0 contact hour.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 4 weeks.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.